Annual Meeting of Shareholders – Results

27 August 2019

NZX and Media Release

TRUSCREEN RESULTS OF ANNUAL SHAREHOLDING MEETING
The Truscreen Limited Annual Meeting of Shareholders was held on 27 August 2019.
Voting was conducted by poll of the shareholders present at the meeting and the proxies
registered. Details of the resolutions and voting results were:
Resolution For Against Abstain/
Disregarded
1 Remuneration of auditor 145,165,692 10,000 168,179
2 Re-election of Mr Chris Horn as a
director

144,161,882

953,810

228,179
3 Re-election of Mr Kelly Hickey as a
director

145,115,692

0

228,179
4 Remuneration of non-executive
directors

83,526,312

1,947,145

59,870,414
5 Ratification of prior issue of
7,142,856 shares

145,030,195

95,781

217,895
6 Ratification of prior issue of
9,677,363 shares

144,868,766

257,210

217,895
7 Ratification pf prior issue of
9,677,363 options

144,468,766

657,210

217,895
8 Issue of placement shares and
share options – Anthony Ho

144,605,525

558,747

179,599
9 Issue of up to 10,000,000 options
to senior executives and directors

81,821,319

1,978,053

61,544,499

Guy Robertson
CFO
guyrobertson@truscreen.com

About TruScreen:
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen-
ultra-video/
TruScreen is a Cervical Cancer Screening Device
which offers the latest technology in cervical
screening, providing real-time, accurate detection
of pre-cancerous and cancerous cervical cells to
help improve the health and well-being of women
around the world. TruScreen’s real-time cervical cancer
technology utilises a digital wand which is placed on the surface
of the cervix to measure electrical and optical signals from the
surrounding tissues. A sophisticated proprietary algorithm
framework is utilised to detect pre-cancerous change, or cervical
intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.
TruScreen offers an alternative approach to cervical screening, resolving many of the
ongoing issues with Pap tests including failed samples, poor patient follow up, patient
discomfort and the need for supporting laboratory infrastructures. As such, TruScreen
target market is developing countries where no large scale cervical cancer screening
programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India.
TruScreen’s cervical cancer screening device is EC certified for use throughout Europe and
CFDA approved for sale in China. Truscreen gained recognition from Global NGO’s WHO and
Unitaid in a joint Cervical Cancer Technology Landscape released at the 72
nd
World Health
Assembly.
For more information, visit our website at www.truscreen.com